CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

But we do have all these great treatments, and we're hoping that the overall survival of those patients will keep getting longer and longer, and maybe one day myeloma could be potentially cured. I ...

Our NAV-005 antagonist binds the immunosuppressive HIO-1 factor and blocks its ability to suppress mAb, TCE and ADC ...

Natural killer cells act as the immune system’s rapid-response team, but the stress of anxiety and insomnia may be quietly thinning their ranks. A study of young women in Saudi Arabia found that both ...

This article is authored by Dr Amrit Kaur Kaler, consultant, molecular pathology, Kokilaben Dhirubhai Ambani Hospitals, ...

Southampton PhD student Lara Graham’s immunotherapy research has taken on new meaning after it helped her mother’s cancer ...

Recent advances in chimeric antigen receptor (CAR) T cell therapy have transformed the treatment landscape of multiple myeloma, yet almost all patients ultimately relapse. Chromosomal 1q gains are ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

Stage 3 multiple myeloma is defined by high beta-2 microglobulin, elevated LDH, and high-risk genetic abnormalities. Diagnosis involves CRAB criteria and tests like bone marrow biopsy, imaging, and ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.